{
    "analysis_session": {
        "id": "session_20250218_002",
        "timestamp": "2025-02-18T14:44:33+08:00"
    },
    "analysis_id": "a_20250218_002",
    "entity_recognition_ref": "er_20250218_002",
    "indication_analysis_ref": "ia_20250218_002",
    "similarity_analysis": {
        "mechanism": {
            "score": 0.85,
            "explanation": "西地那非通过抑制PDE5来改善肺动脉高压，同时对特发性肺纤维化患者的运动耐量和生活质量有潜在改善作用"
        },
        "clinical": {
            "score": 0.80,
            "explanation": "临床研究表明西地那非可改善IPF合并PAH患者的运动能力和血流动力学指标"
        }
    },
    "evidence_analysis": {
        "drug_label": {
            "content": "适应症：治疗肺动脉高压，改善运动能力和血流动力学指标",
            "confidence": 0.90,
            "extraction_time": "2025-02-18T14:44:33+08:00"
        },
        "clinical_guidelines": {
            "guideline_id": "guideline_002",
            "section_id": "rec_002",
            "content": "对于IPF合并PAH的患者，可考虑使用PAH靶向治疗药物，但需要严密监测",
            "confidence": 0.85,
            "extraction_time": "2025-02-18T14:44:33+08:00"
        },
        "expert_consensus": {
            "consensus_id": "consensus_002",
            "content": "特发性肺纤维化合并肺动脉高压时，在权衡获益风险后可考虑使用西地那非等PAH靶向药物",
            "confidence": 0.80,
            "extraction_time": "2025-02-18T14:44:33+08:00"
        }
    },
    "risk_assessment": {
        "benefit_factors": [
            {
                "factor": "改善肺动脉高压",
                "score": 0.85,
                "evidence": "临床研究显示可显著改善肺动脉压力和心输出量",
                "source": {
                    "consensus_id": "consensus_002",
                    "evidence_type": "clinical_trials"
                }
            },
            {
                "factor": "改善运动耐量",
                "score": 0.80,
                "evidence": "可改善6分钟步行距离和呼吸困难症状",
                "source": {
                    "consensus_id": "consensus_002",
                    "evidence_type": "clinical_trials"
                }
            }
        ],
        "risk_factors": [
            {
                "factor": "对原发病进展的不确定性",
                "score": 0.30,
                "evidence": "目前缺乏长期安全性数据",
                "source": {
                    "guideline_id": "guideline_002",
                    "evidence_type": "expert_opinion"
                }
            },
            {
                "factor": "不良反应",
                "score": 0.20,
                "evidence": "可能出现头痛、面部潮红等不良反应，但总体耐受性良好"
            }
        ],
        "benefit_risk_ratio": 0.75
    }
}
